Blinatumomab Maintenance After Allo-HSCT
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age16-65
SponsorRuijin Hospital
About this trial
To evaluate the safety and efficacy of Blinatumomab maintenance after allogeneic hematopoietic stem cell transplantation for high-risk acute B-lymphoblastic leukemia.
Eligibility criteria
Qualifiers
Age 16-65 years
Diagnosis with acute B-lymphoblastic leukemia (B-ALL) expressed CD19
High-risk group B-ALL
Have suitable hematopoietic stem cell donors
Disqualifiers
CR/MRD negative before blinatumomab maintenance
Active hepatitis B
HIV-infected
Active infections; acute and chronic GVHD requiring systemic immunosuppressive therapy;
Trial design
Treatments tested in this trial
- Blinatumomab
Treatment groups
59 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov